HRP20231533T1 - Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave - Google Patents
Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave Download PDFInfo
- Publication number
- HRP20231533T1 HRP20231533T1 HRP20231533TT HRP20231533T HRP20231533T1 HR P20231533 T1 HRP20231533 T1 HR P20231533T1 HR P20231533T T HRP20231533T T HR P20231533TT HR P20231533 T HRP20231533 T HR P20231533T HR P20231533 T1 HRP20231533 T1 HR P20231533T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- compound
- pharmaceutical preparation
- systemic mastocytosis
- mastocytosis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- DWYRIWUZIJHQKQ-SANMLTNESA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1 DWYRIWUZIJHQKQ-SANMLTNESA-N 0.000 title 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- 201000009004 Indolent systemic mastocytosis Diseases 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000006343 Cutaneous Mastocytosis Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 208000008585 mastocytosis Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 1
- 208000032391 Smoldering systemic mastocytosis Diseases 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Kristalni Oblik A spoja (I):
[image]
karakteriziran difraktogramom rendgenskog praha koji ima signal na najmanje tri dvo-teta vrijednosti odabrane između 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2 i 21.6 ± 0.2; ili karakteriziran difraktogramom rendgenskog praha koji ima signal na najmanje sedam dvo-teta vrijednosti odabranih između 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 20.0 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2 i 30.7 ± 0.2.
2. Kristalnin Oblik A prema zahtjevu 1, karakteriziran difraktogramom rendgenskog praha koji ima signal na najmanje osam dvo-teta vrijednosti odabranih između 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 20.0 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2 i 30.7 ± 0.2.
3. Kristalni Oblik A prema zahtjevu 1, karakteriziran difraktogramom rendgenskog praha koji ima signal na dvo-teta vrijednosti od 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 200 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2 i 30.7 ± 0.2.
4. Kristalni Oblik A prema zahtjevu 1, karakteriziran difraktogramom rendgenskog praha koji ima signal na dvo-teta vrijednosti od 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2 i 21.6 ± 0.2.
5. Kristalni Oblik A prema bilo kojem od zahtjeva 1-4, karakteriziran DSC termogramom koji ima endotermni događaj sa signalom na temperaturi u rasponu od 194 °C do 195 °C ili početnoj temperaturi od 193 °C.
6. Kristalni Oblik A spoja (I) prema bilo kojem od zahtjeva 1-5, naznačen time, da je pripravljen postupkom koji sadrži:
otapanje spoja (I) u mješavini acetona i vode da se dobije suspenzija;
[image]
zagrijavanje suspenzije do temperature u rasponu od 40°C do 50°C da se dobije otopina; i
hlađenje otopine.
7. Postupak za pripremu kristalnog Oblika A spoja (I), naznačen time, da sadrži
otapanje spoja (I) u mješavini acetona i vode da se dobije suspenzija;
[image]
zagrijavanje suspenzije do temperature u rasponu od 40°C do 50°C da se dobije otopina; i
hlađenje otopine.
8. Farmaceutski pripravak, naznačen time, da sadrži:
najmanje jedan farmaceutski prihvatljiv ekscipijent; i
kristalni Oblik A spoja (I) prema bilo kojem od zahtjeva 1-6.
9. Kristalni Oblik A spoja (I) prema bilo kojem od zahtjeva 1-6 ili farmaceutski pripravak prema zahtjevu 8, naznačen time, da je za uporabu u postupku liječenja mastocitoze, navedeni postupak sadrži davanje pacijentu kojem je to potrebno terapeutski učinkovite količine navedenog kristalnog oblika A ili farmaceutskog pripravka.
10. Kristalni Oblik A ili farmaceutski pripravak za uporabu prema zahtjevu 9, naznačen time, da je mastocitoza odabrana između kožne mastocitoze (CM) i sistemske mastocitoze (SM).
11. Kristalni Oblik A ili farmaceutski pripravak za uporabu prema zahtjevu 10, naznačen time, da je sistemska mastocitoza odabrana između indolentne sistemske mastocitoze (ISM), tinjajuće sistemske mastocitoze (SSM), i uznapredovale sistemske mastocitoze (AdvSM).
12. Kristalni Oblik A ili farmaceutski pripravak za uporabu prema zahtjevu 11, naznačen time, da je sistemska mastocitoza uznapredovala sistemska mastocitoza (AdvSM), izborno gdje se kristalni oblik A spoja (I) daje jednom dnevno u terapeutski učinkovitoj količini od 200 mg.
13. Kristalni Oblik A ili farmaceutski pripravak za uporabu prema zahtjevu 11, naznačen time, da je sistemska mastocitoza indolentna sistemska mastocitoza (ISM), izborno gdje se kristalni oblik A spoja (I) daje jednom dnevno u terapeutski učinkovitoj količini od 25 mg.
14. Kristalni Oblik A spoja (I) prema bilo kojem od zahtjeva 1-6 ili farmaceutski pripravak prema zahtjevu 8, naznačen time, da je za uporabu u postupku liječenja gastrointestinalnog stromalnog tumora, dok navedeni postupak sadrži davanje pacijentu kojem je to potrebno terapeutski učinkovite količine navedenog kristalnog oblika A ili farmaceutskog pripravka, izborno gdje se kristalni oblik A spoja (I) daje jednom dnevno u terapeutski učinkovitoj količini od 300 mg.
15. Kristalni Oblik A ili farmaceutski pripravak za uporabu prema zahtjevu 14, naznačen time, da je gastrointestinalni stromalni tumor karakteriziran mutacijom egzona 18 u PDGFRα.
16. Kristalni Oblik A spoja (I) prema bilo kojem od zahtjeva 1-6 ili farmaceutski pripravak prema zahtjevu 8, naznačen time, da je za uporabu u postupku liječenja akutne mijeloične leukemije, gdje navedeni postupak sadrži davanje pacijentu kojem je to potrebno terapeutski učinkovite količine navedenog kristalnog oblika A ili farmaceutskog pripravka.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833527P | 2019-04-12 | 2019-04-12 | |
| US201962844575P | 2019-05-07 | 2019-05-07 | |
| US202062990269P | 2020-03-16 | 2020-03-16 | |
| PCT/US2020/027724 WO2020210669A1 (en) | 2019-04-12 | 2020-04-10 | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| EP20722936.0A EP3856341B1 (en) | 2019-04-12 | 2020-04-10 | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231533T1 true HRP20231533T1 (hr) | 2024-03-01 |
Family
ID=70476546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231533TT HRP20231533T1 (hr) | 2019-04-12 | 2020-04-10 | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20210147433A1 (hr) |
| EP (2) | EP3856341B1 (hr) |
| JP (1) | JP2022526438A (hr) |
| CN (1) | CN113966334A (hr) |
| CA (1) | CA3136707A1 (hr) |
| DK (1) | DK3856341T3 (hr) |
| ES (1) | ES2966512T3 (hr) |
| FI (1) | FI3856341T3 (hr) |
| HR (1) | HRP20231533T1 (hr) |
| HU (1) | HUE064283T2 (hr) |
| IL (1) | IL287148A (hr) |
| LT (1) | LT3856341T (hr) |
| MA (1) | MA53759A (hr) |
| PL (1) | PL3856341T3 (hr) |
| PT (1) | PT3856341T (hr) |
| RS (1) | RS64881B1 (hr) |
| SI (1) | SI3856341T1 (hr) |
| TW (1) | TW202104232A (hr) |
| WO (1) | WO2020210669A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2923888T3 (es) | 2013-10-17 | 2022-10-03 | Blueprint Medicines Corp | Procedimiento para preparar composiciones útiles para tratar trastornos relacionados con la KIT |
| DK3856341T3 (da) | 2019-04-12 | 2023-12-04 | Blueprint Medicines Corp | Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf |
| EP3997090A1 (en) * | 2019-07-09 | 2022-05-18 | Sandoz AG | Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| US20230103724A1 (en) | 2020-03-11 | 2023-04-06 | Teva Czech Industries S.R.O | Solid state forms of avapritinib and process for preparation thereof |
| US20230279009A1 (en) | 2020-06-17 | 2023-09-07 | Teva Czech Industries S.R.O | Solid state forms of avapritinib salts |
| HU231413B1 (hu) * | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| EP4301758A1 (en) | 2021-03-03 | 2024-01-10 | Blueprint Medicines Corporation | Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases |
| HUP2200323A1 (hu) * | 2022-08-11 | 2024-02-28 | Egyt Gyogyszervegyeszeti Gyar | Új avapritinib sók és elõállítási eljárásaik |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DE60026297T2 (de) | 1999-05-21 | 2006-11-02 | Bristol-Myers Squibb Co. | Pyrrolotriazin kinasehemmer |
| AU770600B2 (en) | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| DK1497019T3 (en) | 2002-04-23 | 2015-08-03 | Bristol Myers Squibb Co | PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1611131B1 (en) | 2003-02-27 | 2010-09-15 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1755607A2 (en) | 2004-04-29 | 2007-02-28 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5256047B2 (ja) | 2006-01-27 | 2013-08-07 | シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド | ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤 |
| KR101443400B1 (ko) | 2006-07-07 | 2014-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 피롤로트리아진 키나제 억제제 |
| KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| MX2010010151A (es) | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
| KR20100003912A (ko) | 2008-07-02 | 2010-01-12 | 삼성전자주식회사 | 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| US20130023497A1 (en) | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| MX2012009561A (es) | 2010-02-17 | 2012-11-23 | Amgen Inc | Carboxamidas como inhibidores de canales de sodio dependientes del voltaje. |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US10227357B2 (en) | 2012-09-06 | 2019-03-12 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| ES2923888T3 (es) * | 2013-10-17 | 2022-10-03 | Blueprint Medicines Corp | Procedimiento para preparar composiciones útiles para tratar trastornos relacionados con la KIT |
| WO2015061572A1 (en) | 2013-10-25 | 2015-04-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| MX2018002407A (es) | 2015-08-26 | 2018-11-29 | Blueprint Medicines Corp | Compuestos y composiciones utiles para tratar trastornos relacionados con ntrk. |
| US20170119760A1 (en) | 2015-10-28 | 2017-05-04 | Ab Science | Use of masitinib for the treatment of progressive supranuclear palsy |
| JP6807385B2 (ja) | 2015-11-02 | 2021-01-06 | ブループリント メディシンズ コーポレイション | Ｒｅｔの阻害剤 |
| WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| MX2018012664A (es) | 2016-04-15 | 2019-03-07 | Blueprint Medicines Corp | Inhibidores de quinasa tipo receptor de activina. |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| KR20200115606A (ko) * | 2018-01-31 | 2020-10-07 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| TW202039862A (zh) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| DK3856341T3 (da) | 2019-04-12 | 2023-12-04 | Blueprint Medicines Corp | Krystallinske former af (s)-1-(4-fluorphenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin og fremgangsmåder til fremstilling deraf |
| EP3997090A1 (en) | 2019-07-09 | 2022-05-18 | Sandoz AG | Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor |
| GB201915447D0 (en) | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| WO2021091846A1 (en) * | 2019-11-04 | 2021-05-14 | Blueprint Medicines Corporation | Treatment of mast cell diseases and eosinophilic disorders |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
-
2020
- 2020-04-10 DK DK20722936.0T patent/DK3856341T3/da active
- 2020-04-10 JP JP2021560265A patent/JP2022526438A/ja active Pending
- 2020-04-10 FI FIEP20722936.0T patent/FI3856341T3/fi active
- 2020-04-10 PL PL20722936.0T patent/PL3856341T3/pl unknown
- 2020-04-10 PT PT207229360T patent/PT3856341T/pt unknown
- 2020-04-10 HR HRP20231533TT patent/HRP20231533T1/hr unknown
- 2020-04-10 HU HUE20722936A patent/HUE064283T2/hu unknown
- 2020-04-10 SI SI202030328T patent/SI3856341T1/sl unknown
- 2020-04-10 MA MA053759A patent/MA53759A/fr unknown
- 2020-04-10 EP EP20722936.0A patent/EP3856341B1/en active Active
- 2020-04-10 TW TW109112270A patent/TW202104232A/zh unknown
- 2020-04-10 ES ES20722936T patent/ES2966512T3/es active Active
- 2020-04-10 WO PCT/US2020/027724 patent/WO2020210669A1/en active Application Filing
- 2020-04-10 EP EP23195076.7A patent/EP4302761A3/en active Pending
- 2020-04-10 CA CA3136707A patent/CA3136707A1/en active Pending
- 2020-04-10 RS RS20231131A patent/RS64881B1/sr unknown
- 2020-04-10 CN CN202080042782.9A patent/CN113966334A/zh active Pending
- 2020-04-10 LT LTEPPCT/US2020/027724T patent/LT3856341T/lt unknown
-
2021
- 2021-01-20 US US17/153,727 patent/US20210147433A1/en active Pending
- 2021-10-10 IL IL287148A patent/IL287148A/en unknown
-
2022
- 2022-12-08 US US18/077,466 patent/US11964980B2/en active Active
- 2022-12-08 US US18/077,431 patent/US20230124801A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI3856341T3 (fi) | 2023-11-30 |
| US20230271971A1 (en) | 2023-08-31 |
| PT3856341T (pt) | 2023-12-12 |
| EP4302761A2 (en) | 2024-01-10 |
| PL3856341T3 (pl) | 2024-03-04 |
| TW202104232A (zh) | 2021-02-01 |
| SI3856341T1 (sl) | 2024-02-29 |
| EP3856341B1 (en) | 2023-09-06 |
| CA3136707A1 (en) | 2020-10-15 |
| US20230124801A1 (en) | 2023-04-20 |
| HUE064283T2 (hu) | 2024-02-28 |
| WO2020210669A1 (en) | 2020-10-15 |
| EP4302761A3 (en) | 2024-03-27 |
| MA53759A (fr) | 2021-08-04 |
| ES2966512T3 (es) | 2024-04-22 |
| IL287148A (en) | 2021-12-01 |
| RS64881B1 (sr) | 2023-12-29 |
| US11964980B2 (en) | 2024-04-23 |
| JP2022526438A (ja) | 2022-05-24 |
| CN113966334A (zh) | 2022-01-21 |
| LT3856341T (lt) | 2023-12-27 |
| US20210147433A1 (en) | 2021-05-20 |
| EP3856341A1 (en) | 2021-08-04 |
| DK3856341T3 (da) | 2023-12-04 |
| US20240132510A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| JP6946194B2 (ja) | キナーゼを調節する化合物の固体形態 | |
| JP2022058395A5 (hr) | ||
| TW202019900A (zh) | Ptpn11抑制劑 | |
| BR112019028235A2 (pt) | formulações de cinases moduladoras de um composto | |
| JP6749422B2 (ja) | プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物 | |
| KR20180054657A (ko) | Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법 | |
| WO2012125544A2 (en) | Necroptosis inhibitors and methods of use therefor | |
| US20220098152A1 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| JP4484524B2 (ja) | １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体 | |
| CN104761507B (zh) | 氨基喹唑啉衍生物及其在药物中的应用 | |
| AU2019214193B2 (en) | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases | |
| JP4958379B2 (ja) | １−［アルキル］，１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−ピリジニル−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体 | |
| JP2018537486A (ja) | キノロン類似体及びその塩の結晶形 | |
| TW202115091A (zh) | 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法 | |
| AU2020322990B2 (en) | Class of triaromatic compounds targeting bifunctional phosphorylation site of STAT3 and applications thereof | |
| KR101818130B1 (ko) | 1,3,7-삼치환된 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 유도체가 포함된 급성골수성백혈병 치료제 | |
| JP7169695B2 (ja) | ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（１） | |
| JPWO2018159613A1 (ja) | ピラゾロ［３，４−ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤 | |
| JP7282787B2 (ja) | ピラゾロ［３，４－ｄ］ピリミジンの結晶 | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| CN109415382A (zh) | 皮质抑素类似物 | |
| WO2022228363A1 (zh) | 一种组合物的医药用途 | |
| JP2008536901A (ja) | １Ｈ−ピリミド［４，５−ｂ］インドール誘導体、これらの調製及び治療的使用 | |
| Trivedi et al. | Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature |